Importantly, modulation of IL-6 by targeting its upstream mediator IL-1 was recently shown to reduce cardiovascular event rates in CAD patients with previous MI and sustained low-grade inflammation defined as a CRP level of ≥ 2 mg/L7. This evidence concerns the gene IL6 and coronary artery disorder.